Taipei, April 10 (CNA) Taiwan's Academia Sinica said Friday that it has screened out protease inhibitors of the COVID-19 coronavirus, which could eventually lead to the development of targeted drugs to stop the virus from replicating itself in patients' bodies.
Proteases -- groups of enzymes that break down proteins -- act as catalysts in a range of biological processes, and in the context of a virus, are often essential for the completion of the viral infectious cycle.
Protease inhibitors, which can be naturally-occurring or synthetic, block the replication of the virus, and are commonly used in the treatment of human immunodeficiency virus (HIV) and hepatitis C virus.
In a press release, the government research institute said that a team led by Liang Po-huang (梁博煌), a research fellow at the Institute of Biological Chemistry, has screened out potent inhibitors of the virus' main protease (3C-like protease) from more than 100 possible inhibitors.
Read more: Focus Taiwan
ABOUT PTIC TAIPEI
The Philippine Trade & Investment Center in Taipei is the Commercial Affairs Section of the Manila Economic and Cultural Office and the representative office of the Philippine Department of Trade & Industry in Taiwan